{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:42:19Z","timestamp":1790685739164,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T00:00:00Z","timestamp":1547596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["N01 MH-90003"],"award-info":[{"award-number":["N01 MH-90003"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R25MH101078"],"award-info":[{"award-number":["R25MH101078"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Metabolomics is a developing and promising tool for exploring molecular pathways underlying symptoms of depression and predicting depression recovery. The Absolute<jats:italic>IDQ<\/jats:italic>\u2122 p180 kit was used to investigate whether plasma metabolites (sphingomyelins, lysophosphatidylcholines, phosphatidylcholines, and acylcarnitines) from a subset of participants in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial could act as predictors or biologic correlates of depression recovery. Participants in this trial were assigned to one of three pharmacological treatment arms: escitalopram monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination. Plasma was collected at baseline in 159 participants and again 12 weeks later at study exit in 83 of these participants. Metabolite concentrations were measured and combined with clinical and sociodemographic variables using the hierarchical lasso to simultaneously model whether specific metabolites are particularly informative of depressive recovery. Increased baseline concentrations of phosphatidylcholine C38:1 showed poorer outcome based on change in the Quick Inventory of Depressive Symptoms (QIDS). In contrast, an increased ratio of hydroxylated sphingomyelins relative to non-hydroxylated sphingomyelins at baseline and a change from baseline to exit suggested a better reduction of symptoms as measured by QIDS score. All metabolite-based models performed superior to models only using clinical and sociodemographic variables, suggesting that metabolomics may be a valuable tool for predicting antidepressant outcomes.<\/jats:p>","DOI":"10.1038\/s41398-018-0349-6","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T12:03:16Z","timestamp":1548072196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Can targeted metabolomics predict depression recovery? Results from the CO-MED trial"],"prefix":"10.1038","volume":"9","author":[{"given":"Andrew H.","family":"Czysz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"South","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharathi S.","family":"Gadad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0934-0808","authenticated-orcid":false,"given":"Erland","family":"Arning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Soyombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodoro","family":"Bottiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-1110","authenticated-orcid":false,"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,16]]},"reference":[{"key":"349_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.nbd.2009.02.019","volume":"35","author":"MP Quinones","year":"2009","unstructured":"Quinones, M. P. & Kaddurah-Daouk, R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol. Dis. 35, 165\u2013176 (2009).","journal-title":"Neurobiol. Dis."},{"key":"349_CR2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31887\/DCNS.2014.16.1\/dmartins","volume":"16","author":"D Martins-de-Souza","year":"2014","unstructured":"Martins-de-Souza, D. Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. Dialog. Clin. Neurosci. 16, 63\u201373 (2014).","journal-title":"Dialog. Clin. Neurosci."},{"key":"349_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/gps.1690","volume":"22","author":"LA Paige","year":"2007","unstructured":"Paige, L. A., Mitchell, M. W., Krishnan, K. R. R., Kaddurah-Daouk, R. & Steffens, D. C. A preliminary metabolomic analysis of older adults with and without depression. Int. J. Geriatr. Psychiatry 22, 418\u2013423 (2007).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"349_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jpsychires.2012.11.001","volume":"47","author":"A Demirkan","year":"2013","unstructured":"Demirkan, A. et al. Plasma phosphatidylcholine and sphingomyelin concentrations are associated with depression and anxiety symptoms in a Dutch family-based lipidomics study. J. Psychiatr. Res. 47, 357\u2013362 (2013).","journal-title":"J. Psychiatr. Res."},{"key":"349_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010635","volume":"5","author":"J Assies","year":"2010","unstructured":"Assies, J. et al. Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS ONE 5, e10635 (2010).","journal-title":"PLoS ONE"},{"key":"349_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2012.142","volume":"3","author":"R Kaddurah-Daouk","year":"2013","unstructured":"Kaddurah-Daouk, R. et al. Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo. Transl. Psychiatry 3, e223 (2013).","journal-title":"Transl. Psychiatry"},{"key":"349_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/tp.2011.22","volume":"1","author":"R Kaddurah-Daouk","year":"2011","unstructured":"Kaddurah-Daouk, R. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl. Psychiatry 1, 26 (2011).","journal-title":"Transl. Psychiatry"},{"key":"349_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.145","volume":"6","author":"DM Rotroff","year":"2016","unstructured":"Rotroff, D. M. et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Transl. Psychiatry 6, e894 (2016).","journal-title":"Transl. Psychiatry"},{"key":"349_CR9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/mp.2016.6","volume":"21","author":"M Gupta","year":"2016","unstructured":"Gupta, M. et al. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol. Psychiatry 21, 1717\u20131725 (2016).","journal-title":"Mol. Psychiatry"},{"key":"349_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068283","volume":"8","author":"H Zhu","year":"2013","unstructured":"Zhu, H. et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder\u2014possible role for methoxyindole pathway. PLoS ONE 8, e68283 (2013).","journal-title":"PLoS ONE"},{"key":"349_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/clpt.2010.250","volume":"89","author":"Y Ji","year":"2011","unstructured":"Ji, Y. et al. Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram\/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin. Pharmacol. Ther. 89, 97\u2013104 (2011).","journal-title":"Clin. Pharmacol. Ther."},{"key":"349_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135437","volume":"10","author":"M Carayol","year":"2015","unstructured":"Carayol, M. et al. Reliability of serum metabolites over a two-year period: a targeted metabolomic approach in fasting and non-fasting samples from EPIC. PLoS ONE 10, e0135437 (2015).","journal-title":"PLoS ONE"},{"key":"349_CR13","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1021\/acs.analchem.6b02930","volume":"89","author":"AP Siskos","year":"2017","unstructured":"Siskos, A. P. et al. Interlaboratory reproducibility of a targeted metabolomics platform for analysis of human serum and plasma. Anal. Chem. 89, 656\u2013665 (2017).","journal-title":"Anal. Chem."},{"key":"349_CR14","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jalz.2015.12.008","volume":"12","author":"R Casanova","year":"2016","unstructured":"Casanova, R. et al. Blood metabolite markers of preclinical Alzheimer\u2019s disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 12, 815\u2013822 (2016).","journal-title":"Alzheimers Dement."},{"key":"349_CR15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.dadm.2015.05.003","volume":"1","author":"K Klavins","year":"2015","unstructured":"Klavins, K. et al. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer\u2019s disease and mild cognitive impairment. Alzheimers Dement. (Amst.). 1, 295\u2013302 (2015).","journal-title":"Alzheimers Dement. (Amst.)."},{"key":"349_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3233\/JAD-142319","volume":"44","author":"T Koal","year":"2015","unstructured":"Koal, T., Klavins, K., Seppi, D., Kemmler, G. & Humpel, C. Sphingomyelin SM (d18:1\/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-beta42, tau, and phospho-tau-181 levels. J. Alzheimers Dis. 44, 1193\u20131201 (2015).","journal-title":"J. Alzheimers Dis."},{"key":"349_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20, 415\u2013418 (2014).","journal-title":"Nat. Med."},{"issue":"Suppl. 4","key":"349_CR18","doi-asserted-by":"publisher","first-page":"iv86","DOI":"10.1093\/ndt\/gfv252","volume":"30","author":"MJ Pena","year":"2015","unstructured":"Pena, M. J. et al. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrol. Dial. Transplant. 30(Suppl. 4), iv86\u2013iv95 (2015).","journal-title":"Nephrol. Dial. Transplant."},{"key":"349_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0960-3","volume":"14","author":"MJ Pena","year":"2016","unstructured":"Pena, M. J. et al. Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. J. Transl. Med. 14, 203 (2016).","journal-title":"J. Transl. Med."},{"key":"349_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/CIRCGENETICS.116.001444","volume":"9","author":"ME Lacruz","year":"2016","unstructured":"Lacruz, M. E. et al. Cardiovascular risk factors associated with blood metabolite concentrations and their alterations during a 4-year period in a population-based cohort. Circ. Cardiovasc Genet. 9, 487\u2013494 (2016).","journal-title":"Circ. Cardiovasc Genet."},{"key":"349_CR21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"349_CR22","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1214\/13-AOS1096","volume":"41","author":"J Bien","year":"2013","unstructured":"Bien, J., Taylor, J. & Tibshirani, R. A lasso for hierarchical interactions. Ann. Stat. 41, 1111 (2013).","journal-title":"Ann. Stat."},{"key":"349_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","volume":"168","author":"AJ Rush","year":"2011","unstructured":"Rush, A. J. et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 168, 689\u2013701 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"349_CR24","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.4088\/JCP.v69n1201","volume":"69","author":"PJ McGrath","year":"2008","unstructured":"McGrath, P. J. et al. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J. Clin. Psychiatry 69, 1847\u20131855 (2008).","journal-title":"J. Clin. Psychiatry"},{"key":"349_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1017\/S0033291712001742","volume":"43","author":"SC Sung","year":"2013","unstructured":"Sung, S. C. et al. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. Psychol. Med. 43, 945\u2013960 (2013).","journal-title":"Psychol. Med."},{"key":"349_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush, A. J. et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 54, 573\u2013583 (2003).","journal-title":"Biol. Psychiatry"},{"key":"349_CR27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.biopsych.2005.08.022","volume":"59","author":"AJ Rush","year":"2006","unstructured":"Rush, A. J. et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol. Psychiatry 59, 493\u2013501 (2006).","journal-title":"Biol. Psychiatry"},{"key":"349_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/10618600.2014.938812","volume":"24","author":"M Lim","year":"2015","unstructured":"Lim, M. & Hastie, T. Learning interactions via hierarchical group-lasso regularization. J. Comput. Graph. Stat. 24, 627\u2013654 (2015).","journal-title":"J. Comput. Graph. Stat."},{"key":"349_CR29","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing (Vienna, Austria 2016) https:\/\/www.r-project.org\/."},{"key":"349_CR30","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/bioinformatics\/btq688","volume":"27","author":"J Li","year":"2011","unstructured":"Li, J., Das, K., Fu, G., Li, R. & Wu, R. The Bayesian lasso for genome-wide association studies. Bioinformatics 27, 516\u2013523 (2011).","journal-title":"Bioinformatics"},{"key":"349_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fgene.2013.00270","volume":"4","author":"P Waldmann","year":"2013","unstructured":"Waldmann, P., Meszaros, G., Gredler, B., Fuerst, C. & Solkner, J. Evaluation of the lasso and the elastic net in genome-wide association studies. Front. Genet. 4, 270 (2013).","journal-title":"Front. Genet."},{"key":"349_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/10673220802277938","volume":"16","author":"HL Van","year":"2008","unstructured":"Van, H. L., Schoevers, R. A. & Dekker, J. Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harv. Rev. Psychiatry 16, 225\u2013234 (2008).","journal-title":"Harv. Rev. Psychiatry"},{"key":"349_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi, M. H. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28\u201340 (2006).","journal-title":"Am. J. Psychiatry"},{"key":"349_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.euroneuro.2011.07.010","volume":"22","author":"ES Friedman","year":"2012","unstructured":"Friedman, E. S. et al. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur. Neuropsychopharmacol. 22, 183\u2013199 (2012).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"349_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jad.2013.11.026","volume":"160","author":"AK Parsaik","year":"2014","unstructured":"Parsaik, A. K. et al. Statins use and risk of depression: a systematic review and meta-analysis. J. Affect Disord. 160, 62\u201367 (2014).","journal-title":"J. Affect Disord."},{"key":"349_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.bbalip.2009.12.004","volume":"1801","author":"H Hama","year":"2010","unstructured":"Hama, H. Fatty acid 2-Hydroxylation in mammalian sphingolipid biology. Biochim. Biophys. Acta 1801, 405\u2013414 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"349_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-14-124","volume":"14","author":"I Scheid","year":"2013","unstructured":"Scheid, I. et al. Heterozygous FA2H mutations in autism spectrum disorders. BMC Med. Genet. 14, 124 (2013).","journal-title":"BMC Med. Genet."},{"key":"349_CR38","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00702-005-0374-5","volume":"112","author":"J Kornhuber","year":"2005","unstructured":"Kornhuber, J. et al. High activity of acid sphingomyelinase in major depression. J. Neural Transm. (Vienna) 112, 1583\u20131590 (2005).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"349_CR39","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0014-5793(04)00033-X","volume":"559","author":"M Kolzer","year":"2004","unstructured":"Kolzer, M., Werth, N. & Sandhoff, K. Interactions of acid sphingomyelinase and lipid bilayers in the presence of the tricyclic antidepressant desipramine. FEBS Lett. 559, 96\u201398 (2004).","journal-title":"FEBS Lett."},{"key":"349_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1176\/jnp.23.2.jnp215","volume":"23","author":"P Gracia-Garcia","year":"2011","unstructured":"Gracia-Garcia, P. et al. Elevated plasma ceramides in depression. J. Neuropsychiatry Clin. Neurosci. 23, 215\u2013218 (2011).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"349_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tips.2014.04.003","volume":"35","author":"J Kornhuber","year":"2014","unstructured":"Kornhuber, J., Muller, C. P., Becker, K. A., Reichel, M. & Gulbins, E. The ceramide system as a novel antidepressant target. Trends Pharmacol. Sci. 35, 293\u2013304 (2014).","journal-title":"Trends Pharmacol. Sci."},{"key":"349_CR42","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/npp.2014.256","volume":"40","author":"AH Czysz","year":"2015","unstructured":"Czysz, A. H., Schappi, J. M. & Rasenick, M. M. Lateral diffusion of G\u03b1s in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. Neuropsychopharmacology 40, 766\u2013773 (2015).","journal-title":"Neuropsychopharmacology"},{"key":"349_CR43","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1046\/j.1471-4159.1995.64020724.x","volume":"64","author":"J Chen","year":"1995","unstructured":"Chen, J. & Rasenick, M. M. Chronic treatment of C6 glioma cells with antidepressant drugs increases functi. J. Neurochem. 64, 724\u2013732 (1995).","journal-title":"J. Neurochem."},{"key":"349_CR44","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1124\/jpet.109.162644","volume":"332","author":"L Zhang","year":"2010","unstructured":"Zhang, L. & Rasenick, M. M. Chronic treatment with escitalopram but not R-citalopram translocates G alpha S from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compound. J. Pharmacol. Exp. Ther. 332, 977 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"349_CR45","first-page":"509","volume":"275","author":"J Chen","year":"1995","unstructured":"Chen, J. & Rasenick, M. Chronic antidepressant treatment facilitates G protein activation of adenylyl cyclase without altering G protein content. J. Pharmacol. Exp. Ther. 275, 509 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"349_CR46","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1523\/JNEUROSCI.5713-07.2008","volume":"28","author":"RJ Donati","year":"2008","unstructured":"Donati, R. J. et al. Postmortem brain tissue of depressed suicides reveals increased gs alpha localization in lipid raft domains where it is less likely to activate adenylyl cyclase. J. Neurosci. 28, 3042 (2008).","journal-title":"J. Neurosci."},{"key":"349_CR47","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1161\/01.ATV.20.12.2614","volume":"20","author":"XC Jiang","year":"2000","unstructured":"Jiang, X. C. et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 20, 2614\u20132618 (2000).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"349_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1743-7075-3-5","volume":"3","author":"A Schlitt","year":"2006","unstructured":"Schlitt, A. et al. Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutr. Metab. (Lond.) 3, 5 (2006).","journal-title":"Nutr. Metab. (Lond.)"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0349-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0349-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T07:08:07Z","timestamp":1720940887000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-018-0349-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1038\/s41398-018-0349-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,16]]},"assertion":[{"value":"15 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MHT has served as a consultant or on the advisory board for Alkeremes Inc., Akili Interactive, Navitor, Otsuka America Pharmaceutical Inc., Allergan Pharmaceuticals, Lundbeck Research USA, Medscape, MSI Methylation Sciences \u2013 Pamlab Inc., One Carbon Therapeutics, Takeda Global Research, Avanir Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development. He has received grants from the National Institute of Mental Health (NIMH), National Institute of Drug Abuse (NIDA), National Center for Advancing Translational Sciences (NCATS), Cancer Prevention and Research Institute of Texas (CPRIT), the Patient-Centered Outcomes Research Institute (PCORI), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Agency for Healthcare Research and Quality (AHRQ), Johnson & Johnson. He has received honoraria from the American Psychiatric Association. The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"11"}}